Complement regulatory protein expression by a human oligodendrocyte cell line: Cytokine regulation and comparison with astrocytes

Immunology

Volumn 89, Issue 3, 1996, Pages 338-347

  Gasque, P ^a   Morgan, B P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT RECEPTOR; CYTOKINE; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA;

ARTICLE; ASTROCYTE; CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OLIGODENDROGLIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029799125     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1996.d01-756.x     Document Type: Article

References (38)

1. MORGAN B.P. (1995) Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 265.
2. FRANK M.M. & FRIES L.F. (1991) The role of complement in inflammation and phagocytosis. Immunol Today 12, 322.
3. VOLANAKIS J.E. (1995) Transcriptional regulation of complement genes. Ann Rev Immunol 13, 277.
4. MORGAN B.P. (1993) Complement in diseases of the nervous system. In: Complement in Health and Disease (eds K. Whaley, M. Loos & J.M. Weiler), p. 353. Kluwer Academic Publishers, the Netherlands, Dordrecht.
5. WREN D.R & NOBLE M. (1989) Oligodendrocytes and oligodendrocyte/type 2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. Proc Natl Acad Sci USA 86, 9025.
6. SCOLDING, N.J., MORGAN B.P., HOUSTON W.A.J., LININGTON C., CAMPBELL A.K. & COMPSTON D.A.S. (1989) Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339, 620.
7. ROGERS J., COOPER N.R., WEBSTER S. et al. (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89, 10016.
8. GASQUE P., JULEN N., ISCHENKO A.M. et al. (1992) Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149, 1381.
9. GASQUE P., ISCHENKO A.M., LEGOEDEC J., MAUGER C., SCHOUFT M.T. & FONTAINE M. (1993) Expression of the complement classical pathway by human glioma in culture. J Biol Chem 268, 25068.
10. GASQUE P., FONTAINE M. & MORGAN B.P. (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 154, 4726.
11. WING, M.G. ZAJICEK J., SEILLY D.J, COMPSTON D.A.S. & LACHMANN P.J. (1992) Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology 76, 140.
12. PIDDLESDEN S.J. & MORGAN B.P. (1993) Killing of rat glial cells by complement: Deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J Neuroimmunol 48, 169.
13. CYONG J.C., WITKIN S.S., RIEGER B., BARBARESE E., GOOD R.A. & DAY N.K (1992) Antibody-independent complement activation by myelin via the classical complement pathway. J Exp Med 155, 587.
14. VANGURI P., KOSKI C.L., SILVERMAN B. & SHIN M.L. (1982) Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci USA 79, 3290.
15. RISTIC G.A. & DAWSON G. (1989) Characterization of a clonal cell line from a human oligodendroglioma. Trans Am Soc Neurochem 20, 101.
16. KASHIMA T., TIU S.N., MERRILL J.E., VINTERS H.V., DAWSON G. & CAMPAGNONI A.T. (1993) Expression of oligodendrocyte-associated genes in cell lines derived from human gliomas and neuroblastomas. Cancer Res 53, 170.
17. KASHIMA T., VINIERS H.V. & CAMPAGNONI A.T. (1995) Unexpected expression of intermediate filament protein genes in human oligodendroglioma cell lines. J Neuropathol Exp Neurol 54, 23.
18. PEUDENIER S., HERY C., MONTAGNIER L. & TARDIEU M. (1991) Human microglial cells: Characterization in cerebral tissue and primary culture, and study of their susceptibility to HIV-1 infection. Ann Neurol 29, 152.
19. SEBIRE G., EMILIE D., WALTON C. et al. (1993) In vitro production of IL-6, Il-1β, and tumor necrosis factor-α by human embryonic microglial and neural cells. J Immunol 150, 1517.
20. MARCHBANK K.J., MORGAN B.P. & VAN DEN BERG, C.W. (1995) Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross linking antibody and non lethal complement attack. Immunology 85, 146.
21. LISZEWSKI M.K., POST T.W. & ATKINSON J.P. (1991) Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Ann Rev Immunol 9, 431.
22. LUBLIN D.M. & ATKINSON J.P. (1989) Decay-accelerating factor: Biochemistry, molecular biology, and function. Ann Rev Immunol 7, 35.
23. RUIJS T.C.G., OLIVIER A. & ANIEL J.P. (1990) Serum cytotoxicity to human and rat oligodendrocytes in culture. Brain Res 517, 99.
24. ZAJICEK K., WING M., SKEPPER J. & COMPSTON A. (1995) Human oligodendrocytes are not sensitive to complement: a study of CD59 expression in the human central nervous system. Lab Invest 73, 128.
25. VEDELER C., ULVESTAD E., BJORGE L. et al. (1994) The expression of CD59 in normal human nervous tissue. Immunology 82, 542.
26. ZAJICEK J., WING M.G., LACHMANN P.J. & COMPSTON D.A.S. (1992) Mechanisms of oligodendrocyte interaction with normal human serum defining the role of complement. J Neurol Sci 108, 65.
27. MEDOF M.E., WALTER E.I., RUTGERS J.L., KNOWLES D.M. & NUSSENZWEIG V. (1987) Identification of the complement decay-accelerating factor(DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165, 848.
28. ROONEY I.A. & MORGAN B.P. (1992) Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 76, 541.
29. HARA T., KURIYAMA S., KIYOHARA H., NAGASE Y., MATSUMOTO Y. & SEYA T. (1992) Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects. Clin Exp Immunol 89, 490.
30. MERI S., WALDMANN H. & LACHMANN P.J. (1991) Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65, 532.
31. NOSE M., KATOH M., OKADA N., KYOGOKU M. & OKADA H. (1990) Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in viro. Immunology 70, 145.
32. JOHNSTONE R.W., LOVELAND B.E. & MCKINZIE I.F.C. (1993) Identification and quantification of complement regulator CD46 on normal human tissues. Immunology 79, 341.
33. KUMAR S., VINCI J.M., PYTEL B.A. & BAGLIONI C. (1993) Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 53, 348.
34. JOHNSON S.A., LAMPERT-ETCHELLS M. PASINETTI G.M., ROZOVSKY I. & FINCH C.E. (1992) Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging 13, 641.
35. WALKER D.G. & MCGEER P.L. (1992) Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Mol Brain Res 14, 109.
36. VEERHUIS R., JANSSEN I., HACK E. & EIKELENBOOM P. (1996) Early complement components in Alzheimer's disease brains. Acta Neuropathol 91, 53.
37. PIDDLESDEN S., LASSMANN H., LAFFAFIAN I., MORGAN B.P. & LININGTON C. (1991) Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin Exp Immunol 83, 245.
38. PIDDLESDEN S.J., STORCH M.K., HIBBS M., FREEMAN A.M., LASSMANN H. & MORGAN B.P. (1994) Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 152, 5477.